A young woman of 29 years lies confined to her parents’ home in the United Kingdom, her life devastated by long COVID for nearly two years. She is unable to move without experiencing severe physical distress, unable to speak without triggering debilitating migraines, and unable to open her eyes without suffering intense pain and cognitive impairment. This is not a transient illness but a relentless condition that threatens her survival—her respiratory function or cognitive capacity at risk of permanent failure without intervention.

A potential treatment, Sipavibart, offers a glimmer of hope. Dr. Elisa Astorri, a distinguished rheumatologist at Rheumatology Harley Street, contends that this drug can substantially alleviate symptoms and, in some cases, facilitate near-complete recovery for those afflicted with long COVID.

Her clinic states the following;

"Dr Astorri has been using Evusheld for 5 years to treat immunocompromised patients with a 99.9% success.

In January 2024 she started treating Long Covid patients with raised spike protein levels and she has had wonderful outcomes.

Astra Zeneca developed the new Evusheld called Sipavibart in July 2024. Evusheld has always been available for private prescriptions but for some reason the new Government doesn’t allow the use of Sipavibart in the UK.

As you can imagine our Practice has hundreds of patients on these Monoclonals after 5 years of using them.

We have contacted AZ and the Government to try to understand why Evusheld was allowed but his better version Sipavibart is not, especially  considering that this has no effect on the NHS, we only do private prescriptions.

We have had no relevant answers. Nevertheless our Pharmacy is confident that Sipavibart will be available in the first quarter of 2025. We do not have a date."

This approach finds support in AstraZeneca’s SUPERNOVA Phase III trial (May 2024), which demonstrated Sipavibart’s efficacy in preventing symptomatic COVID-19 in immunocompromised individuals.

Yet, the Medicines and Healthcare products Regulatory Agency (MHRA) has not approved Sipavibart for this purpose, hindered by prolonged bureaucratic processes. There is a further concern that AstraZeneca may cease production of the drug if regulatory approval is not forthcoming, placing commercial interests above human lives. This young woman—once vibrant and intelligent—represents one of approximately two million individuals in the UK enduring the profound and debilitating effects of long COVID, a public health crisis that demands immediate action.

The approval of Sipavibart for long COVID treatment is not merely a regulatory matter—it is a moral imperative. The MHRA, the Secretary of State for Health and Social Care, Wes Streeting MP, and all relevant authorities must act with urgency to make this drug available without further delay. This petition calls upon the public to lend their voices by signing and sharing widely, compelling decision-makers to prioritize this critical intervention. Approximately two million lives hang in the balance; inaction risks condemning countless individuals to an irreversible fate